CL2023002578A1 - Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos - Google Patents
Derivados de alfa-d-galatopiranosido triazolil-metil sustituidosInfo
- Publication number
- CL2023002578A1 CL2023002578A1 CL2023002578A CL2023002578A CL2023002578A1 CL 2023002578 A1 CL2023002578 A1 CL 2023002578A1 CL 2023002578 A CL2023002578 A CL 2023002578A CL 2023002578 A CL2023002578 A CL 2023002578A CL 2023002578 A1 CL2023002578 A1 CL 2023002578A1
- Authority
- CL
- Chile
- Prior art keywords
- galatopyranoside
- triazolyl
- derivatives
- methyl substituted
- substituted alpha
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la Fórmula (I), en donde A, R1, R2, RP2, RP3 y RP4 son como se describe en la descripción, su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I), y especialmente a su uso como inhibidores de Galectina-3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002578A1 true CL2023002578A1 (es) | 2024-03-22 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002578A CL2023002578A1 (es) | 2021-03-03 | 2023-08-31 | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (es) |
| EP (1) | EP4301748A1 (es) |
| JP (1) | JP2024509421A (es) |
| KR (1) | KR20230154221A (es) |
| CN (1) | CN116888113A (es) |
| AU (1) | AU2022228660A1 (es) |
| BR (1) | BR112023017624A2 (es) |
| CA (1) | CA3209917A1 (es) |
| CL (1) | CL2023002578A1 (es) |
| IL (1) | IL305581A (es) |
| MX (1) | MX2023010241A (es) |
| TW (1) | TW202300146A (es) |
| WO (1) | WO2022184755A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| CA2926917C (en) | 2012-10-10 | 2021-01-05 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| ES2817888T3 (es) | 2012-10-31 | 2021-04-08 | Galecto Biotech Ab | Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar |
| WO2014078655A1 (en) | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| CN107406478B (zh) | 2015-01-30 | 2021-07-27 | 格莱克特生物技术公司 | 半乳糖凝集素的α-D-半乳糖苷抑制剂 |
| JP6430060B2 (ja) | 2015-07-06 | 2018-11-28 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｏｔモジュレーターおよびその使用方法 |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| CA3062649A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2019075045A1 (en) | 2017-10-11 | 2019-04-18 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| CN111527097A (zh) | 2017-10-31 | 2020-08-11 | 卡莱克汀科学有限责任公司 | 用于治疗全身性胰岛素抵抗障碍的硒代半乳糖苷化合物及其用途 |
| JP7486484B2 (ja) | 2018-11-21 | 2024-05-17 | ガレクト バイオテック エービー | ガレクチンのα－Ｄ－ガラクトシド阻害剤 |
| WO2020210308A1 (en) * | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| CA3141436A1 (en) | 2019-07-03 | 2021-01-07 | Fredrik Zetterberg | Novel galactoside inhibitor of galectins |
| EP3994135A1 (en) | 2019-07-05 | 2022-05-11 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
| TW202120102A (zh) | 2019-08-09 | 2021-06-01 | 瑞士商愛杜西亞製藥有限公司 | (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| WO2021028570A1 (en) | 2019-08-15 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | 2-hydroxycycloalkane-1-carbamoyl derivatives |
| RS65294B1 (sr) | 2019-08-29 | 2024-04-30 | Idorsia Pharmaceuticals Ltd | Derivati alfa-d-galaktopiranozida |
-
2022
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 JP JP2023552539A patent/JP2024509421A/ja active Pending
- 2022-03-02 TW TW111107565A patent/TW202300146A/zh unknown
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 EP EP22708569.3A patent/EP4301748A1/en active Pending
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en active Application Filing
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022184755A1 (en) | 2022-09-09 |
| EP4301748A1 (en) | 2024-01-10 |
| TW202300146A (zh) | 2023-01-01 |
| JP2024509421A (ja) | 2024-03-01 |
| CA3209917A1 (en) | 2022-09-09 |
| MX2023010241A (es) | 2023-09-12 |
| AU2022228660A1 (en) | 2023-10-19 |
| IL305581A (en) | 2023-10-01 |
| CN116888113A (zh) | 2023-10-13 |
| KR20230154221A (ko) | 2023-11-07 |
| BR112023017624A2 (pt) | 2023-10-10 |
| US20240109930A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| BRPI0819328A8 (pt) | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos | |
| BR112014030173A8 (pt) | Composto derivado de benzimidazol-prolina, e, composição farmacêutica | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| UY31069A1 (es) | Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones | |
| BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
| BR122019010008B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
| AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BR112014000713A2 (pt) | derivados de indol substituído como moduladores de gama secretase | |
| BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
| BR112013023984A2 (pt) | derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase | |
| SV2009003199A (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| BRPI0720742B8 (pt) | derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos | |
| BRPI0511999A (pt) | compostos como antagonistas de ccr5 | |
| CU20100157A7 (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BR112012032748A2 (pt) | "compostos de piridina anelados" | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| BR112021018692A2 (pt) | 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| UY30356A1 (es) | Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos. |